

Executive Summary

A high-yield ancillary revenue program for high-image and risk adverse private orthopedic practices.

A national market leader in cold-compression therapy (CCT), treating over 50,000 worker compensation patients, WRS has introduced an innovative practice based program to dispense complex “rental based” DME products for controlling post operative pain, reducing opioid consumption, and enhancing the recovery process.

Compliant

Compliance is the cornerstone for all revenue generating activity in healthcare today. The ORS program has been vetted by experienced counsel for regulatory compliance and where appropriate, we validated key aspects of our compliance analysis with state regulators.

Sustainable

As a process driven company, ORS provides best in class technology and ongoing operational support. Patients and physicians benefit from consistent and safe outcomes from CCT therapy over the lifetime of the program.

Profitable

Proactive and transparent engagement with payors to seek prior authorization is the foundation for meaningful and consistent revenue. ORS manages the billing, collecting, and reporting of every financial transaction.

Program KPI's

- 76% of patients report taking fewer narcotics
- 94% Patient Satisfaction Score with CCT
- >\$1,100 anticipated net profit to the practice per approved patient.
- 2 approved Rx's recoup the cost of a CCT unit




The WRS Difference

- Longevity and reputational excellence among payors and practices
- Patient-centric care and service model
- Dedicated team for ongoing support and optimization to the practice



Redacted Ortho Group Account Statement December 2023

Net to Practice	Current Month	Lifetime
Total Collections	\$47,299.50	\$286,093.91
Less ORS Fees	(\$23,176.76)	(\$140,186.02)
Practice Net Profit	\$24,122.74	\$145,907.89
Less Fixed Asset Payments	\$0.00	(\$60,730.00)
Less Disposable Payments	(\$747.00)	(\$13,237.50)
Less Call Center and Financing Payments	(\$15.00)	(\$2,570.49)
Net to Practice	\$23,360.74	\$69,369.90



Practice Net Profit Per Approved Patient	\$2,017
Est. Outstanding Net AR. (as of 12/31/2023)	\$51.8K
Initial Approval Percentage	94%
Extension Approval Percentage	92%

Fixed Asset Inventory		Current Month	Lifetime
Beginning Balance	\$	-	-
Purchases	Units		
CCT Units	0	28	60,730.00
SAM Units	0	0	-
Total Purchases	\$	\$	\$ 60,730.00
Ending Balance	\$	\$	\$ 60,730.00

Financing Activity		Current Month	Lifetime
Beginning Balance	\$	-	-
Add Fixed Asset Purchases	\$	-	\$ 60,730.00
Add Disposable Purchases	\$	747.00	13,237.50
Add Call Center Fee	\$	15.00	180.00
Add Finance Charge	\$	-	2,390.49
Less Payments	\$	(762.00)	(76,537.99)
Ending Balance	\$	\$0.00	\$0.00

Asset Financing Fee		Current Month	Lifetime
Beginning Balance	\$	\$0.00	
Financing Interest Rate	%	8.50%	
Total Financing Fee	\$	\$	\$ 2,390.49